A. Scherpereel, F. Wallyn, S. M. Albelda, and C. Munck, Novel therapies for malignant pleural mesothelioma, Lancet Oncol, vol.19, issue.3, pp.161-172, 2018.

K. Oehl, B. Vrugt, I. Opitz, and M. Meerang, Heterogeneity in malignant pleural mesothelioma, Int J Mol Sci, vol.19, issue.6, 2018.

A. De-reynies, M. C. Jaurand, A. Renier, G. Couchy, I. Hysi et al., Molecular classification of malignant pleural mesothelioma: Identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition, Clin Cancer Res, vol.20, issue.5, pp.1323-1334, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02478599

R. Bueno, E. W. Stawiski, L. D. Goldstein, S. Durinck, D. Rienzo et al., Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nat Genet, vol.48, issue.4, pp.407-416, 2016.

J. Hmeljak, F. Sanchez-vega, K. A. Hoadley, J. Shih, C. Stewart et al., Integrative molecular characterization of malignant pleural mesothelioma, Cancer Discov, vol.8, issue.12, pp.1548-1565, 2018.

A. N. Husain, T. Colby, N. Ordonez, T. Krausz, R. Attanoos et al., Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the international mesothelioma interest group, Arch Pathol Lab Med, vol.137, issue.5, pp.647-667, 2013.

Y. Blum, C. Meiller, L. Quetel, N. Elarouci, M. Ayadi et al., Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications, Nat Commun, vol.10, issue.1, p.1333, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02090279

D. Jean, J. Daubriac, L. Pimpec-barthes, F. Galateau-salle, F. et al., Molecular changes in mesothelioma with an impact on prognosis and treatment, Arch Pathol Lab Med, vol.136, issue.3, pp.277-293, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02478588

B. Thapa, A. Salcedo, X. Lin, M. Walkiewicz, C. Murone et al., The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma, J Thorac Oncol, vol.12, issue.5, pp.850-859, 2017.

A. Scherpereel, J. Mazieres, L. Greillier, S. Lantuejoul, P. Do et al., Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (ifct-1501 maps2): A multicentre, open-label, randomised, non-comparative, phase 2 trial, Lancet Oncol, vol.20, issue.2, pp.239-253, 2019.